Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories

An update from Kalray SA ( ($FR:ALKAL) ) is now available. Kalray has disclosed its updated share capital structure, reporting 15,412,938 shares ou...

Kalray Publishes Updated Share Capital and Voting Rights Structure

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX) and Abbott Laboratories (ABT...

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Abbott Laboratories (ABT)

Investors on the hunt for a fast-growing dividend need look no further than Abbott Laboratories ($ABT). In December of last year, Abbott increased ...

This Leading Pharma Company Has Grown Its Dividend 70% Since 2020

Fears over a possible stagflation – a period of high inflation and stagnant economic growth – have been on the rise since oil prices spiked amid th...

Wall Street’s 3 Safe Bets as Fed’s Powell Downplays Stagflation, But Sees ‘Some Tension Between the ​Goals’

Abitare In SpA ( ($IT:ABT) ) has provided an update. Abitare In S.p.A., a Milan-based residential developer listed on the Euronext STAR Milan segme...

Abitare In to Present Urban Regeneration Strategy at Euronext STAR Conference 2026

The Schwab U.S. Dividend Equity ETF ($SCHD) has been one of the strongest performers of 2026, outgaining the S&P 500 ($SPX) by over 12% so far this...

SCHD ETF Slips Ahead of Portfolio Reshuffle — UNH, QCOM In; HAL, VLO Out

The U.S.-Iran war has sent oil prices up, triggering concerns of stagflation, a period of high inflation and slow economic growth. The job market s...

3 ‘Strong Buy’ Stocks Analysts Recommend as Stagflation Fears Emerge

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT – Research Report) and Kura...

Market Cap	$177.35B	P/E Ratio	18.30
52W High	$139.06	52W Low	$100.88
Div Yield	252.0%	Payout Ratio	208.4%
EPS Growth 3Y	24.6%	52W Position	7.0%
Overall Score	54	Value Score	90
Quality Score	55	Technical Score	18

EPS Current Est	$5.66	EPS Next Est	$6.23
EPS Growth Est	+10.1%	DPS Growth 3Y	7.6%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABT	$103.56	0.00%	8.29M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABT	$103.56	0%	8.29M
3
4
5
6

ABT

ABT

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Abbott Laboratories Data in Excel

Get Abbott Laboratories Data in Excel